These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19091441)

  • 1. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
    Ma S; Xu Y; Deng Q; Yu X
    Lung Cancer; 2009 Aug; 65(2):198-203. PubMed ID: 19091441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
    Welsh JW; Komaki R; Amini A; Munsell MF; Unger W; Allen PK; Chang JY; Wefel JS; McGovern SL; Garland LL; Chen SS; Holt J; Liao Z; Brown P; Sulman E; Heymach JV; Kim ES; Stea B
    J Clin Oncol; 2013 Mar; 31(7):895-902. PubMed ID: 23341526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
    Pesce GA; Klingbiel D; Ribi K; Zouhair A; von Moos R; Schlaeppi M; Caspar CB; Fischer N; Anchisi S; Peters S; Cathomas R; Bernhard J; Kotrubczik NM; D'Addario G; Pilop C; Weber DC; Bodis S; Pless M; Mayer M; Stupp R
    Eur J Cancer; 2012 Feb; 48(3):377-84. PubMed ID: 22093943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
    Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
    Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
    Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
    Lin CH; Hsu KH; Chang SN; Tsou HK; Sheehan J; Sheu ML; Pan HC
    Radiat Oncol; 2015 Jun; 10():127. PubMed ID: 26048754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
    Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
    Iuchi T; Shingyoji M; Sakaida T; Hatano K; Nagano O; Itakura M; Kageyama H; Yokoi S; Hasegawa Y; Kawasaki K; Iizasa T
    Lung Cancer; 2013 Nov; 82(2):282-7. PubMed ID: 24021541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.
    Ge XH; Lin Q; Ren XC; Liu YE; Chen XJ; Wang DY; Wang YQ; Cao B; Li ZG; Liu ML
    Radiat Oncol; 2013 Oct; 8():238. PubMed ID: 24125485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
    Wang Q; Jiang Z; Qi X; Lu S; Wang S; Leng C; Lu F; Liu H; Liang S; Shi J
    Clin Transl Oncol; 2014 Nov; 16(11):1000-5. PubMed ID: 24894840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
    Ceresoli GL; Cappuzzo F; Gregorc V; Bartolini S; Crinò L; Villa E
    Ann Oncol; 2004 Jul; 15(7):1042-7. PubMed ID: 15205197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
    Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
    J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
    Fu H; Zhang XL; Xiao Y; Liu XJ; Long C; Hu YD
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):524-7. PubMed ID: 22490154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
    Namba Y; Kijima T; Yokota S; Niinaka M; Kawamura S; Iwasaki T; Takeda Y; Kimura H; Okada T; Yamaguchi T; Nakagawa M; Okumura Y; Maeda H; Ito M
    Clin Lung Cancer; 2004 Sep; 6(2):123-8. PubMed ID: 15476598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K; Jiang G; Zhang A; Li Z; Jia J
    BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.